DAWN (Day One Biopharmaceuticals) Net Income (Continuing Operations): $-107.3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Net Income (Continuing Operations)?

Day One Biopharmaceuticals DAWN 12 Net Income (Continuing Operations) is $-107.3 Mil as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Day One Biopharmaceuticals's Net Income (Continuing Operations) for the three months ended in Dec. 2025 was $-21.3 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was $-107.3 Mil.

Day One Biopharmaceuticals  (NAS:DAWN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Day One Biopharmaceuticals Net Income (Continuing Operations) Related Terms

Day One Biopharmaceuticals Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Net Income (Continuing Operations) Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -72.75 -142.18 -188.92 -95.50 -107.32

Day One Biopharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.71 -36.00 -30.32 -19.73 -21.28
DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-107.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-107.3 Mil mean?
Day One Biopharmaceuticals (DAWN) has a Net Income (Continuing Operations) of $-107.3 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' Net Income (Continuing Operations) too high?
Day One Biopharmaceuticals' current Net Income (Continuing Operations) is $-107.3 Mil. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Net Income (Continuing Operations) compare to TYRA and DFTX?
Day One Biopharmaceuticals' Net Income (Continuing Operations) of $-107.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Net Income (Continuing Operations) is $-107.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Net Income (Continuing Operations) of $-107.3 Mil. The current Net Income (Continuing Operations) is $-107.3 Mil. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Net Income (Continuing Operations) is $-107.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price